Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from November 1, 2008, to April 30, 2009. The report, dated May 11, 2009, details the status of various employee share option schemes and savings-related plans. It serves as a regulatory disclosure regarding the allotment of securities under these specific compensation programs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a "Block Listing Six Monthly Return" focused on equity compensation inventory rather than operational financial performance.
| Share Option Scheme | Securities Issued/Allotted (Nov 2008 - Apr 2009) | Balance Unallotted (End of Period) |
|---|---|---|
| GlaxoSmithKline Share Option Plan - Ordinary Shares | 702,118 | 5,295,707 |
| GlaxoSmithKline Share Option Plan - ADS | 8,400 | 6,389,424 |
| GlaxoSmithKline Savings Related Share Option Scheme | 922,669 | 5,264,981 |
| Glaxo Wellcome UK Share Option Scheme | 0 | 5,119,750 |
| Glaxo Wellcome International Share Option Scheme | 0 | 13,267,156 |
| Glaxo Wellcome 1999 Share Option Plan | 0 | 1,040,000 |
| SmithKline Beecham 1989 Executive Share Option Plan (Approved) | 0 | 163,606 |
| SmithKline Beecham 1989 Executive Share Option Plan (Unapproved ADS) | 0 | 275,420 |
| SmithKline Beecham 1989 Executive Share Option Plan (Unapproved Ordinary) | 0 | 100,000 |
Material Changes
During the reporting period, no increases were applied for to any of the block schemes. The primary material changes were reductions in the unallotted balances for three specific schemes due to securities being issued or allotted:
- GlaxoSmithKline Share Option Plan (Ordinary Shares): Decreased by 702,118 shares.
- GlaxoSmithKline Share Option Plan (ADS): Decreased by 8,400 shares.
- GlaxoSmithKline Savings Related Share Option Scheme: Decreased by 922,669 shares.
All other listed schemes maintained their previous unallotted balances with zero issuances during this period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory return of share scheme data and contains no forward-looking statements or risk disclosures.
Investor Verification Points
- Verify the total number of shares issued under the Savings Related Share Option Scheme (922,669) against the company's broader equity compensation expense reports.
- Confirm the remaining unallotted capacity for the Glaxo Wellcome International Share Option Scheme, which holds the largest balance at 13,267,156 shares.
- Check subsequent filings to determine if the zero-issuance status of legacy schemes (e.g., SmithKline Beecham 1989 plans) remains consistent.
- Review the company's Form 20-F for the corresponding period to obtain actual financial performance metrics absent from this filing.